A recent study posted to medRxiv* preprint server reported a novel form of post-acute coronavirus disease 2019 (COVID-19) syndrome in children. Study: Acute tubulointerstitial nephritis with or ...

In children with lupus nephritis, neurological manifestations at the time of kidney biopsy, age, and eGFR predicted greater risk of CKD progression. Investigators have identified predictors of chronic ...

MMF induction is a viable alternative to cyclophosphamide for treating mixed proliferative lupus nephritis in children. Oral mycophenolate mofetil (MMF) is as effective as intravenous cyclophosphamide ...

With this approval, pediatric patients aged five years and older with active lupus nephritis will have a first-of-its-kind treatment option for at-home administration. GSK plc (LSE/NYSE: GSK) today ...

Benlysta is a human monoclonal antibody that was approved for the treatment of lupus in adults by the U.S. Food and Drug Administration (FDA) in 2011 and for lupus nephritis in adults in 2020.

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

Although the lupus low disease activity state (LLDAS) has seldom served as a treatment goal in patients with lupus nephritis, it proved an attainable target and effectively predicted the risk for ...

The U.S. Food & Drug Administration (FDA) has granted approval for a new subcutaneous autoinjector formulation of belimumab (Benlysta®) treatment for children ages five years and older with active ...